DPC 681 and DPC 684: Potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 11, 2001, Pages 3021-3028

  Kaltenbach III, R F ^a   Trainor, G ^a   Getman, D ^a   Harris, G ^a   Garber, S ^a   Cordova, B ^a   Bacheler, L ^a   Jeffrey, S ^a   Logue, K ^a   Cawood, P ^a   Klabe, R ^a   Diamond, S ^a   Davies, M ^a   Saye, J ^a   Jona, J ^a   Erickson Viitanen, S ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DMP 681; DMP 684; DPC 681; DPC 684; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SULFONAMIDE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; CHIMERA; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PROTEINS; DOGS; DRUG RESISTANCE, MICROBIAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PROTEIN BINDING; SULFONAMIDES;

EID: 0034769881     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.11.3021-3028.2001     Document Type: Article

References (31)

1. Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells
2. An assay for HIV RNA in infected cell lysates, and its use for rapid evaluation of antiviral efficacy
3. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA panel
4. A randomized, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: The OzCombo 1 study
5. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
6. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
7. Drug resistance and predicted virologic response to human immunodeficiency virus type 1 protease inhibitor therapy
8. Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323
9. HIV genotype and phenotype - Arresting resistance?
10. Clinical outcome of patients with HIV-1 infection acording to immunologic and virologic response after 6 months of highly active antiretroviral therapy
11. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeters or less
12. Kinetics of replication and estimated prevalence in untreated patients
13. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
14. Resistance to antiretroviral drugs - An emerging problem
15. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
16. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild types and protease inhibitor resistant mutants of HIV
17. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
18. The retroviral enzymes
19. Active human immunodeficiency virus protease is required for viral infectivity
20. A preliminary, evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV-1) protease, to treat HIV infection
21. Selection and analysis of human immunodeficiency virus type I vairants with increased resistanct to ABT 538, a novel protease inhibitor
22. Virological failure among patients on HAART from across Europe: Results from the EuroSIDA study
23. Efavirenz: Shifting the HAART paradigm in adult HIV-1 infection
24. In vitro selection and characterization of VX-478 resistant HIV-1 variants
25. Production of resistant HIV mutants during antiretroviral therapy
26. Synthesis and anti-HIV activity of a series of 2-indolinones and related analogs
27. Viral dynamics in human immunodeficiency virus type I infection
28. HIV therapy: Managing resistance
29. Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors
30. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
31. Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production